Toward increased sensitivity and specificity in the treatment of neoplastic diseases.
Slavkin
H C
HC
National Institute of Dental Research, Bethesda, Md 20892-2290, USA.
D043168:Angiostatins; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D016503:Drug Delivery Systems; D015972:Gene Expression Regulation, Neoplastic; D016147:Genes, Tumor Suppressor; D006801:Humans; D016023:Integrins / Q000378:metabolism; D009154:Mutation; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000235:genetics*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D010446:Peptide Fragments / Q000494:pharmacology; D010958:Plasminogen / Q000494:pharmacology; D011485:Protein Binding; D012680:Sensitivity and Specificity
D000970:Antineoplastic Agents; D016023:Integrins; D010446:Peptide Fragments; D043168:Angiostatins; D010958:Plasminogen